

Now Approved with Pass-through Status¹



- Biosimilar to Avastin[®]
- Extended shelf life of up to 30 months vs 24 months for Avastin[®]²
- Supported by the Amneal PATHways[®] patient support program
- CMS Outpatient Prospective Payment System (OPPS) pass-through indicator status of G

| Unit of Sale | Pack of 1 | | Pack of 10 | |
|---|---|-------------------------|---------------|-------------------------|
| | NDC | List (WAC) ³ | NDC | List (WAC) ³ |
| 100 mg/4 mL (25 mg/mL) Single-Dose Vial | 70121-1754-01 | \$718.60 | 70121-1754-07 | \$7,186.00 |
| 400 mg/16 mL (25 mg/mL) Single-Dose Vial | 70121-1755-01 | \$2,874.40 | 70121-1755-07 | \$28,744.00 |
| HCPSC Code ¹ | Descriptor | | | |
| C9142 | Injection, bevacizumab-maly, biosimilar, (almysys), 10 mg (effective 10/1 - 12/31/22) | | | |
| Q Code Pending | Expected in January 2023 | | | |

Pack sizes and presentations available at launch may vary.

IMPORTANT SAFETY INFORMATION

Indications and Usage

Almysys[®] (bevacizumab-maly) in the U.S. is a vascular endothelial growth factor inhibitor indicated for the treatment of:

- Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.
- Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
- First-Line non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel.
- Recurrent glioblastoma in adults.
- Metastatic renal cell carcinoma in combination with interferon alfa.
- Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with paclitaxel

Limitations of Use: Almysys is not indicated for adjuvant treatment of colon cancer.

1. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Recommendations; Third Quarter, 2022 HCPCS Coding Cycle
 2. Periodic Safety Update Report (PSUR) For Almysys[®] (Bevacizumab-maly), 22 April 2022
 3. Wholesale Acquisition Cost (WAC) as of 9/30/2022

All trademarks are property of their respective owners. Images are for reference only; actual product may vary.



Storage & Handling

Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton until time of use to protect from light. Do not freeze or shake the vial or carton.

In-use stability has been demonstrated for 30 days at 2°C to 8°C plus an additional 48 hours at 30°C in sodium chloride 9 mg/mL solution for injection.¹



1-866-4AMNEAL
(426-6325)

Amneal is pleased to offer reimbursement access and patient support services through the PATHways program.

PATHways Patient Access Specialists are available to assist healthcare providers and patients with:

- Benefit investigation
- Prior authorization support
- Affordability options like co-pay savings
- Claims assistance

Call toll-free Monday through Friday, 8 AM to 8 PM ET.

IMPORTANT SAFETY INFORMATION (continued)

Warnings and Precautions

Alymsys® Important Safety Information includes warnings and precautions on severe and fatal hemorrhage; arterial and venous thromboembolic events; hypertension, hypertensive crisis, and hypertensive encephalopathy; renal injury, proteinuria, and nephrotic syndrome; posterior reversible encephalopathy syndrome; embryo-fetal toxicity; ovarian failure; congestive heart failure; gastrointestinal perforations and fistula; surgery and wound healing complications, and infusion-related reactions.

Adverse Reactions

Reported adverse drug reactions in patients include epistaxis, hemorrhage, hypertension, exfoliative dermatitis, proteinuria, back pain, headache, rhinitis, taste alteration, dry skin, and lacrimation disorder.

Visit [Alymsys.us](https://www.alymsys.us) for full Prescribing Information

Alymsys
(bevacizumab-maly)



Order from your wholesaler or contact Amneal: Toll Free 866.525.7270 | CustomerRelations@amneal.com

©2022 Amneal Pharmaceuticals LLC. All rights reserved. ALYPS-03 9.30.22